Who owns GAIN THERAPEUTICS INC?
- Ticker: GANX
- CUSIP Number: 36269b105
Tip: Access positions for across all investors
Analyze quarterly positions in Gain Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Gain Therapeutics stock
Who bought or sold GAIN THERAPEUTICS INC this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Greenlight Capital | 588k | $1.9M | 0% | Dec 2023 |
|
DME Capital Management | 566k | $2.1M | 100% | Mar 2024 |
|
Raymond James & Associates | 260k | $980k | 993% | Mar 2024 |
|
Royal Bank of Canada | 249k | $937k | 24% | Mar 2024 |
|
Geode Capital Management | 177k | $668k | 17% | Mar 2024 |
|
Vanguard Group | 119k | $450k | 35% | Mar 2024 |
|
CM Management | 90k | $339k | 0% | Mar 2024 |
|
BlackRock | 75k | $284k | 170% | Mar 2024 |
|
Susquehanna International | 73k | $276k | 12% | Mar 2024 |
|
Northern Trust | 47k | $175k | 250% | Mar 2024 |
|
Millennium Management | 44k | $167k | 248% | Mar 2024 |
|
Springbok Capital Management | 36k | $135k | -38% | Mar 2024 |
|
Bridgeway Capital Management | 30k | $113k | -35% | Mar 2024 |
|
Simplex Trading | 18k | $67k | 100% | Mar 2024 |
|
Citadel Advisors | 12k | $47k | -83% | Mar 2024 |
|
UBS Group | 8.7k | $33k | -38% | Mar 2024 |
|
Tower Research Capital | 4.6k | $18k | 61% | Mar 2024 |
|
Creekmur Asset Management | 4.4k | $17k | 0% | Mar 2024 |
|
Wells Fargo & Company | 3.8k | $14k | 1% | Mar 2024 |
|
Bank of America Corporation | 3.4k | $13k | 100% | Mar 2024 |
|
Morgan Stanley | 2.8k | $11k | 115% | Mar 2024 |
|
Group One Trading | 2.0k | $7.5k | 3% | Mar 2024 |
|
Citigroup | 684.00 | $2.6k | 100% | Mar 2024 |
|
Goss Wealth Management | 225.00 | $848.002500 | -98% | Mar 2024 |
|
Who sold out of Gain Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Dimensional Fund Advisors | Dec 2023 | 16k | $52k |
Advisor Group Holdings | Dec 2023 | 10k | $33k |